Friday May 25 | Customer Interaction Solutions
Research and Markets: Four-S Fortnightly PharmaHealth Track -...
Research and Markets: Four-S Fortnightly PharmaHealth Track - Newsletter on Indian Healthcare Industry - Issue 5 - Cipla Makes Significant Price Cuts on 3 Cancer Drugs Research and Markets has announced the addition of the "Four-S Fortnightly PharmaHealth Track - Newsletter on Indian Healthcare Industry - Issue 5" report to their offering.
Bayer CropScience's Meredith Lawhon And Bekah Mahan Honored With Triangle Business Journal Awards
RESEARCH TRIANGLE PARK, NC - Planting seeds of beneficial change in the local community and growing a positive company culture are just a few of the specialties of Meredith Lawhon and Bekah Mahan, Bayer CropScience employees who were honored with 2012 "40 Under 40" leadership awards from the Triangle Business Journal recently.
Bayer Backs Xarelto Sales Forecast After FDA Panel Votes Against Expanded Use
FRANKFURT German pharmaceutical company Bayer AG Thursday confirmed it sees peak annual sales of its Xarelto drug above EUR2 billion after a U.S. Food and Drug Administration advisory panel voted against expanded use of the blood thinner.The FDA advisers narrowly voted against the use of the anti-clotting pill to treat patients with a heart problem ... (more)
UPDATE 1-US advisers reject new use for J&J/Bayer's Xarelto
U.S. advisers recommended against expanding the use of Johnson & Johnson's blood thinner Xarelto as a way to reduce the risk of new heart attacks and strokes in people with heart problems.
Bayer HealthCare Pharmaceuticals Submits New Drug Application for...
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia /PRNewswire/ -- Bayer HealthCare announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the oral ... (more)
Bayer Submits Regorafenib For EU, US. Marketing Authorization
FRANKFURT German pharmaceutical company Bayer AG's HealthCare unit Wednesday said it applied for marketing authorization in the E.U. and the U.S. for its oral drug Regorafenib, used to threat patients with metastatic colorectal cancer.MAIN FACTS:-Bayer has applied to the European Medicines Agency and the U.S. Food and Drug Administration.-The ... (more)
City opens 1938 Miles Lab time capsule
After more than 70 years hidden in the steps of the old Bayer building, the city of Elkhart opened a Miles Lab time capsule Tuesday night.
Bayer: Nexavar Lung Cancer Phase III Study Misses Primary Endpoint
German chemical and pharmaceutical group Bayer AG and Onyx Pharmaceuticals, Inc.
Doctor questions new drug's use
A local doctor is questioning whether the German pharmaceutical giant Bayer AG illegally sells and promotes a blood-clotting prevention medicine for a use not approved by China's State Food and Drug Administration.
UPDATE 2-FDA staff sends mixed message on J&J drug Xarelto
U.S. drug reviewers had mixed opinions about whether Johnson & Johnson's blood thinner Xarelto reduced the risk of new heart attacks and strokes in people with heart problems, setting the stage for heated debate by outside experts later this week.
J&J-Bayer Blood Thinner Xarelto Is Recommended for Expanded Use
Johnson & Johnson and Bayer AG 's blood-thinner Xarelto was recommended for approval to prevent heart attacks by a reviewer for U.S. regulators.
TEXT-Fitch revises Bayer's outlook to positive;afrms at 'A-'
May 21 - Fitch Ratings has revised the Outlook on Germany-based healthcare chemicals group Bayer AG's Long-term Issuer Default Rating to Positive from Stable and affirmed the IDR and senior unsecured ratings at 'A'-. The agency has also affirmed the Short-term IDR at 'F2' and Bayer's EUR1.3bn hybrid bond at 'BBB'. "The Positive Outlook reflects ... (more)
AIBA hails patents office's decsion on Nexavar issue
Hyderabad, May 11 : Following the move of German drug maker, Bayer AG, to approach Intellectual Property Appellate Board in the Nexavar battle, the All India Biotech Association - Southern Chapter today appreciated the Indian Patents Office order in favour of Natco Pharma Limited.
OncoMed files for $115 million IPO
The Redwood City-based cancer drug developer, one of the most successful Bay Area biotech companies at raising venture capital over the past five years, said it will use proceeds of the IPO to advance its lead drug -- demcizumab, or OMP-21M18 -- and two other drugs into Phase II clinical trials and for programs with partners GlaxoSmithKline and ... (more)
Bayer CropScience Honored With "A Better World" Award From Triangle Business Journal
RESEARCH TRIANGLE PARK, NC - Bayer CropScience , one of the world's top innovators in the areas of crop protection, non-agricultural pest control, seeds and traits, received an inaugural "A Better World" award from the Triangle Business Journal for the company's passion and commitment to local nonprofit organizations in the Raleigh area in 2011.
Societe Generale Now Covering Bayer AG
The firm set a "hold" rating on the stock. A number of other analysts have also recently weighed in on BAYRY.
InVigorA Canola Supports Communities with More for Everyone Awards
Kids ice-skating in hockey uniforms, working parents needing childcare, teens waiting for the day when they learn agronomy and biology in a greenhouse and many others across North Dakota are joining their canola-growing neighbors in celebrating the benefits of InVigor canola hybrids from Bayer CropScience , as small community groups receive ... (more)
Bayer Could Get EUR1 Billion With Diabetes Device Unit Sale -Report
Germany's Bayer AG has contacted rivals to sound out their interest in buying its diabetes instrument business, German daily Financial Times Deutschland reported Wednesday, citing sources close to the contacted parties and in the financial sector.
Bayer challenges India cancer drug ruling favoring Natco
German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.India's patents chief ruled in March the price Bayer charged for the drug, Nexavar, was "exorbitant" and ordered the firm to give a so-called "compulsory ... (more)
Bayer Appeals India Patent Office Ruling On Cancer-Drug License
Germany's Bayer AG has appealed against the grant of a compulsory license by India's patent authority to a local generic drug producer for its kidney- and liver-cancer medicine, Nexavar.